After pressure, Biogen to expand compassionate use for ALS drug
Following pressure by advocates for patients with amyotrophic lateral sclerosis, or ALS, Biogen has expanded its early access program to an experimental ALS drug called tofersen. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 27, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news
Protein linked to ALS/Ataxia could play key role in other neurodegenerative disorders
(University of Utah Health) A new study suggests that some neurological disorders share a common underlying thread. Staufen1, a protein that accumulates in the brains of patients with certain neurological conditions, is linked to amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, along with other neurological disorders, including Alzheimer's, Parkinson's, and Huntington's disease, according to University of Utah Health scientists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
ION363, the first medicine to specifically target FUS-ALS, is among Ionis' wholly owned assets the company plans to commercialize
ALS portfolio now includes four clinical-stage investigational antisense medicines designed to treat the root causes of gen... Biopharmaceuticals, Neurology Ionis Pharmaceuticals, amyotrophic lateral sclerosis, FUS-ALS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2021 Category: Pharmaceuticals Source Type: news
CRISPR-SNP-chip enables amplification-free electronic detection of single point mutations
(Keck Graduate Institute) Keck Graduate Institute (KGI) Assistant Professor and University of California, Berkeley Visiting Scientist Dr. Kiana Aran first introduced the CRISPR-Chip technology in 2019. Now just two years later, she has expanded on its application to develop CRISPR-SNP-Chip, which enables detection of single point mutations without amplification in Sickle Cell Disease and Amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 5, 2021 Category: Biology Source Type: news
Helixmith Announces First Patient Enrolled in Phase 2 Study of...
Helixmith announced today enrollment of the first patient in a new Phase 2A clinical trial, REViVALS-1A, targeting Amyotrophic Lateral Sclerosis (ALS) using Helixmith’s flagship gene therapy product...(PRWeb March 10, 2021)Read the full story at https://www.prweb.com/releases/helixmith_announces_first_patient_enrolled_in_phase_2_study_of_engensis_vm202_for_amyotrophic_lateral_sclerosis/prweb17786005.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 10, 2021 Category: Pharmaceuticals Source Type: news
Researchers reveal process behind harmful glial cell change in motor neurone disease
(The Francis Crick Institute) Scientists at the Francis Crick Institute and UCL have identified the trigger of a key cellular change in amyotrophic lateral sclerosis (ALS), a type of motor neurone disease. The findings could help develop new treatments for many neurological diseases with the same change, including Parkinson's and Alzheimer's. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 3, 2021 Category: Biology Source Type: news
ALS neuron damage reversed with new compound
(Northwestern University) Scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a key contributor to ALS (amyotrophic lateral sclerosis), a swift and fatal neurodegenerative disease that paralyzes its victims. In ALS, movement-initiating nerve cells in the brain and muscle-controlling nerve cells in the spinal cord die. After administering the new compound,, the diseased brain neurons stopped degenerating so much that they became similar to healthy control neurons after 60 days of treatment. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 23, 2021 Category: International Medicine & Public Health Source Type: news
Researchers find evidence of protein folding at site of intracellular droplets
(University of Notre Dame) Researchers at the University of Notre Dame found that elevated concentrations of proteins within the droplets triggered a folding event, increasing the potential for protein aggregation -- or misfolding -- which has been linked to neurological diseases including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2021 Category: International Medicine & Public Health Source Type: news
Bringing innovation to rare disease patients in Europe
Why is Biogen focusing on rare diseases? About 6,000 different rare diseases have been identified to date and these are estimated to affect 30 million people across Europe. It is essential that we collaborate across the medical community, industry, and governments to develop new therapies, explore new technologies and ensure equitable access to treatment. We must innovate across every aspect of treatment to transform the lives of people in these underserved communities. At Biogen, we have shown that pioneering in neuroscience can change the course of treatment for certain rare diseases. We have transformed the treatmen...
Source: EyeForPharma - February 17, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
For many of the 30 million people affected by rare disease in the EU, lack of effective treatments and discrepancies in access and diagnosis are still common issues. Strong political will, innovation and further cooperation between countries remain vital to improve outcomes and transform their quality of life.To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021.Andrea Corazza, Head of Brussels Liaison Office, Public Policy& Government Affairs, Biogen, says: “With this campaign, we want to help putting...
Source: EyeForPharma - February 11, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Occupational therapy interventions in adults with multiple sclerosis or amyotrophic lateral sclerosis: a scoping review - De-Bernardi-Ojuel L, Torres-Collado L, Garc ía-de-la-Hera M.
This scoping review aims to describe occupational therapy interventions carried out with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) patients in occupational therapy. A peer review of the literature was conducted in different databases:... (Source: SafetyLit)
Source: SafetyLit - February 8, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
The Microglial Component of Amyotrophic Lateral Sclerosis The Microglial Component of Amyotrophic Lateral Sclerosis
The authors explore evidence for the contribution of microglia to neurotoxicity and neuroprotection in amyotrophic lateral sclerosis. Might elucidation of these processes lead to novel therapeutics?Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Poor corticospinal motor neuron health is associated with increased symptom severity in the acute phase following repetitive mild TBI and predicts early ALS onset in genetically predisposed rodents - Alkaslasi MR, Cho NE, Dhillon NK, Shelest O, Haro-Lopez PS, Linaval NT, Ghoulian J, Yang AR, Vit JP, Avalos P, Ley EJ, Thomsen GM.
Traumatic brain injury (TBI) is a well-established risk factor for several neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, however, a link between TBI and amyotrophic lateral sclerosis (ALS) has not been clearly elucidate... (Source: SafetyLit)
Source: SafetyLit - February 6, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Imaging zebrafish movements in 3D to better understand ALS disease
(Institut national de la recherche scientifique - INRS) An interdisciplinary team of the Institut national de la recherche scientifique (INRS) used an innovative imaging technique for a better understanding of motor deficits in Amyotrophic Lateral Sclerosis (ALS). The researchers were able to follow the escape behaviour of normal and disease zebrafish models, in 3D. Their results have recently been published inOptica, the flagship journal of the Optical Society (OSA). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 29, 2021 Category: International Medicine & Public Health Source Type: news
Suicide among veterans with amyotrophic lateral sclerosis - Lund EM, Hostetter TA, Forster JE, Hoffmire CA, Stearns-Yoder KA, Brenner LA, Sohi MT.
INTRODUCTION: The purpose of this study was to estimate the risk of death by suicide for those with amyotrophic lateral sclerosis (ALS) seeking care within the Veteran Health Administration (VHA). METHODS: This was a retrospective, cohort study. Ex... (Source: SafetyLit)
Source: SafetyLit - January 25, 2021 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
